EGFR and Friedreich ataxia: ,46,47 In the particular case of FA, a clinical trial for patients with HNSCC has recently been initiated with the non-genotoxic EGFR signaling inhibitor, afatinib (AFAN trial, EUCT no.: 2024-511477-29-00).48